LFG-500, a newly synthesized flavonoid, induces apoptosis in human ovarian carcinoma SKOV3 cells with involvement of the reactive oxygen species-mitochondria pathway
- Authors:
- Published online on: April 18, 2017 https://doi.org/10.3892/etm.2017.4343
- Pages: 2819-2827
-
Copyright: © Yin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Ovarian cancer is the main cause of gynecologic malignancy-related mortality in women. Therefore, the disease requires improvements in treatment options and in the potency of chemotherapeutic drugs. The study of apoptosis in tumor cells is an important field for cancer therapy and cancer molecular biology. It has recently been established that LFG‑500, a new synthesized flavonoid with a piperazine and benzyl group substitution, has strong anticancer activity. However, its exact molecular mechanism is not fully understood. The present study aimed to examine the effects of LFG‑500 on human ovarian cancer SKOV3 cells, as well as to identify its underlying mechanisms. The data showed that LFG‑500 inhibited the growth of SKOV3 cells in a concentration‑dependent manner. It was found that LFG‑500 induced apoptosis in SKOV3 cells, detected by DAPI staining and an Annexin V/PI double‑staining assay. Moreover, LFG‑500 reduced caspase‑3 protein expression and increased the Bcl‑2‑associated X protein/B‑cell lymphoma 2 protein ratio. Further findings revealed that LFG‑500 treatment resulted in reactive oxygen species (ROS) accumulation and loss of mitochondrial transmembrane potential. Collectively, these results demonstrated that LFG‑500 efficiently induced apoptosis in SKOV3 cells, an event possibly associated with the trigging of the mitochondrial apoptotic pathway through ROS accumulation. Therefore, LFG-500 shows potential as a potent anticancer agent for the treatment of ovarian cancer.
